February 1, 2018Circulation Cardiovascular Interventions
Treatment of Aortic Stenosis With a Self-Expanding, Resheathable Transcatheter Valve
Key result
The Portico TAVI system yielded a 30-day all-cause mortality rate of 3.6% and a 1-year rate of 13.8% in high-risk patients with severe aortic stenosis.
Why the study?
Does the Portico TAVI system improve clinical outcomes and valve function in high-risk patients with symptomatic severe aortic stenosis?
Population
222 high-risk patients with symptomatic severe aortic stenosis, mean age 83.0±4.6 years, 74.3% women, across…
Design
Cohort
Follow-up
1 year
Authors
Discussion
Loading...
Member takes
Implication
Supports Portico TAVI feasibility in high-risk severe AS; leaves open need for randomized comparisons to guide adoption.
Structured PICO
Does the Portico TAVI system improve clinical outcomes and valve function in high-risk patients with symptomatic severe aortic stenosis?
P
Population
222 high-risk patients (mean age 83.0 years, 74.3% women) with symptomatic severe aortic stenosis, followed for up to 1 year.
I
Intervention
Portico TAVI system (resheathable, self-expanding transcatheter aortic valve implantation)
O
Outcome
All-cause mortality at 30 dayshard clinical
The Portico self-expanding, resheathable TAVI system demonstrates safety and efficacy at 1 year with low mortality and stroke rates in high-risk patients with severe aortic stenosis.
Cite This Study
Linke et al. (2018) studied symptomatic severe aortic stenosis (n=222). Portico TAVI system was evaluated on all-cause mortality at 30 days. The Portico TAVI system yielded a 30-day all-cause mortality rate of 3.6% and a 1-year rate of 13.8% in high-risk patients with severe aortic stenosis.